InvestSMART

Zelira Therapeutics Limited (ASX: ZLD) - Announcements

- Current share price for ZLD : $0.500

ASX company news and announcements for Zelira Therapeutics Limited (ZLD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Zelira Therapeutics Limited (ZLD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Zelira Therapeutics Limited (ZLD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Zelira Therapeutics Limited (ZLD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Director Loans 16 Sep 2025 11:58AM $0.380 $0.500 risen by 31.58%
$7 Preliminary Final Report 29 Aug 2025 2:00PM $0.450 $0.500 risen by 11.11%
$7 Preliminary Final Report 29 Aug 2025 2:00PM $0.450 $0.500 risen by 11.11%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2025 4:29PM $0.410 $0.500 risen by 21.95%
$7 Zelira Therapeutics Secures R&D Loan Facility 24 Jul 2025 12:05PM $0.410 $0.500 risen by 21.95%
$7 Publication of ZLT-L-007 IRB Approved Observational Study 22 May 2025 8:21AM $0.495 $0.500 risen by 1.01%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 11:06AM $0.380 $0.500 risen by 31.58%
$7 Full Conversion of $USD3.25M Convertible Notes in HOPE SPV 28 Apr 2025 8:23AM $0.350 $0.500 risen by 42.86%
$7 Investor Presentation 3 Apr 2025 8:17AM $0.480 $0.500 risen by 4.17%
$7 Application for quotation of securities - ZLD 1 Apr 2025 5:49PM $0.480 $0.500 risen by 4.17%
$7 Cleansing Prospectus 31 Mar 2025 1:07PM $0.480 $0.500 risen by 4.17%
$7 Proposed issue of securities - ZLD 31 Mar 2025 12:33PM $0.480 $0.500 risen by 4.17%
$7 Zelira secures $1 Million At-the-Market Funding Facility 31 Mar 2025 8:18AM $0.480 $0.500 risen by 4.17%
$7 Appendix 4D & FY25 Interim Financial Report 26 Feb 2025 8:14PM $0.470 $0.500 risen by 6.38%
$7 Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund 18 Feb 2025 1:32PM $0.500 $0.500 fallen by 0%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 2:08PM $0.590 $0.500 fallen by 15.25%
$7 Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche 28 Jan 2025 8:25AM $0.575 $0.500 fallen by 13.04%
$7 Change of Director's Interest Notice x 2 20 Jan 2025 8:13PM $0.620 $0.500 fallen by 19.35%
$7 Notification of cessation of securities - ZLD 17 Jan 2025 5:19PM $0.630 $0.500 fallen by 20.63%
$7 Change of Director's Interest Notice 19 Dec 2024 5:55PM $0.620 $0.500 fallen by 19.35%
$7 Notification regarding unquoted securities - ZLD 18 Dec 2024 1:15PM $0.610 $0.500 fallen by 18.03%
$7 Zelira to present at Automic Invest 2024 conference 20 Nov 2024 8:51AM $0.660 $0.500 fallen by 24.24%
$7 Proposed issue of securities - ZLD 14 Nov 2024 5:34PM $0.700 $0.500 fallen by 28.57%
$7 Results of Meeting 14 Nov 2024 12:47PM $0.700 $0.500 fallen by 28.57%
$7 2024 Annual General Meeting Presentation 14 Nov 2024 11:02AM $0.700 $0.500 fallen by 28.57%

26 - 50 of 547 results

Page 2 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.